Q1 Earnings Estimate for Neurogene Issued By William Blair

Neurogene Inc. (NASDAQ:NGNE) – Analysts at William Blair issued their Q1 2025 EPS estimates for shares of Neurogene in a report released on Tuesday, March 25th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.92) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene’s Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.70) EPS and FY2026 earnings at ($4.60) EPS.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.05. The business had revenue of $0.93 million during the quarter.

Separately, HC Wainwright dropped their price target on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $59.80.

Neurogene Stock Performance

Shares of NASDAQ NGNE opened at $14.52 on Thursday. The stock’s 50-day simple moving average is $16.88 and its 200-day simple moving average is $28.82. The firm has a market capitalization of $215.69 million, a PE ratio of -3.40 and a beta of 1.01. Neurogene has a fifty-two week low of $13.47 and a fifty-two week high of $74.49.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. acquired a new stake in shares of Neurogene during the fourth quarter worth about $71,000. China Universal Asset Management Co. Ltd. purchased a new stake in Neurogene during the 4th quarter valued at approximately $72,000. Virtus ETF Advisers LLC lifted its position in Neurogene by 45.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock worth $73,000 after acquiring an additional 989 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Neurogene by 192.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock valued at $91,000 after purchasing an additional 1,429 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Neurogene by 34.5% in the 4th quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock valued at $124,000 after purchasing an additional 1,397 shares during the last quarter. 52.37% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This represents a 5.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.92% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.